×
Download 2024 Brochure
OPT Congress returns to Boston in 2025— Mark your calendar for March 11-12!

Thank you for joining us at the 9th Annual OPT Congress!

It was great to see so many new and familiar faces onsite. We are still in awe of what we can accomplish when work together as community. We look forward to welcoming you back to Boston March 12-13, 2025.

View Photo Gallery
Video Highlights

Missed this year’s event?

Purchase On-Demand

We’ve got you covered. Our on-demand platform gives you access to content across all 4 tracks including keynote presentations. At your convenience, view archived presentations for one year, from anywhere at any time.


Oligonucleotide Conference Programs

MARCH 13 - 14

OLIGO DISCOVERY & DELIVERY

OLIGO CMC & REGULATORY STRATEGIES


Pre-Conference, In-Person Dinner Short Course | MARCH 12

Welcome to OPT Congress:
Oligonucleotides & mRNA Therapeutics

OPT Congress is the premier conference for scientists and clinicians involved in discovering and developing oligonucleotides as therapeutics. NEW for 2024 we are delighted to expand our content and offer 2 conference programs dedicated to mRNA therapeutics to complement our established Oligo Discovery & Delivery and CMC & Regulatory programs. Now in its 9th year, this unique event brings together leading chemists, biologists, toxicologists, CMC experts, regulatory specialists and technology providers to discuss advances in next-generation oligonucleotides and mRNA therapeutics. In addition to 2 days of inspiring keynotes, interactive discussions and more than 95 scientific presentations, we deliver an in-depth, pre-conference dinner short course on the safety & toxicity of nucleic acids. We look forward to having you join us for this important scientific and networking event, that offers robust and customizable programming.

View Program
Sponsor and Exhibit Opportunities
2023 Event Highlights
5 Conferences
85+ Speakers
300+ Attendees
150+ Unique Organizations
Pre Conference Short Courses

2024 Plenary Speakers

Jeffery M. Coller

Jeffery M. Coller, PhD
Bloomberg Distinguished Professor of RNA Biology and Therapeutics, Johns Hopkins University

Arthur Krieg, MD

Arthur Krieg, MD
Adjunct Professor, University of Massachusetts, Chan School of Medicine

Mano Manoharan, PhD

Mano Manoharan, PhD
Distinguished Scientist & Senior Vice President, Innovation Chemistry, Alnylam Pharmaceuticals

Laura Sepp-Lorenzino

Laura Sepp-Lorenzino, PhD
CSO, Intellia Therapeutics

Our Executive Advisory Board

Dmitry Samarsky, PhD

Dmitry Samarsky, PhD
CTO, Sirnaomics

Muthiah (Mano) Manoharan, PhD

Muthiah (Mano) Manoharan, PhD
Senior Vice President, Drug Discovery, Alnylam Pharmaceuticals

Arthur Levin, PhD

Arthur Levin, PhD
CSO, Avidity Biosciences

Lubo Nechev, PhD

Lubo Nechev, PhD
Vice President Process and Analytical Sciences, Alnylam Pharmaceuticals

Ekkehard Leberer, PhD

Ekkehard Leberer, PhD
Senior Life Sciences Consultant, ELBIOCON

Chandra Vargeese, PhD

Chandra Vargeese, PhD
CTO & Head, Platform Discovery Sciences, Wave Life Sciences